Health secretary slams abortion pill ruling as ‘not America’
Becerra told CNN’s State of the Union: “We want the courts to overturn this reckless decision” so women can continue to have “access to a drug that’s proven itself safe”. “Mifepristone is one of the safest and most effective medicines that we have seen over the last 20 years to help women with their health care”, he said
The nation’s top health official said Sunday that a court ruling threatening the availability of a main drug used in medication abortion was “not America” and he did not rule out defying the judge’s order if necessary.
“We want the courts to overturn this reckless decision,” Xavier Becerra, President Joe Biden’s health secretary, told CNN’s “State of the Union.” “We want, yes, that women continue to have access to a drug that’s proven itself safe. Millions of women have used this drug around the world.”
He stressed that for now, women do have access to the abortion medication mifepristone after a federal judge in Texas, Donald Trump-appointee Matthew Kacsmaryk, put his ruling from Friday on hold for a week so federal officials could file a challenge. The drug was approved in 2000 by the Food and Drug Administration, which is overseen by the Health and Human Services Department headed by Becerra.
Biden said his administration would fight the Texas ruling. Kacsmaryk’s 67-page order gave the government seven days to appeal.
“We intend to do everything to make sure it’s available to them not just in a week, but moving forward, period, because mifepristone is one of the safest and most effective medicines that we have seen over the last 20 years to help women with their health care, especially abortion care,” Becerra said.
Asked whether he might recommend that the FDA ignore a ban, Becerra said, “Everything is on the table.”
There is uncertainty about access to the most commonly used method of abortion in the United States following two separate and conflicting court rulings in Texas and Washington over the legality of mifepristone.
Kacsmaryk’s decision ordering a hold on federal approval of mifepristone overruled decades of scientific approval. But a ruling at nearly the same time in Washington state from that U.S. District Judge Thomas O. Rice, a Barack Obama appointee, directed U.S. authorities not to make any changes that would restrict access to the drug in at least 17 states where Democrats sued in an effort to protect availability.
Becerra said Kacsmaryk’s order could have dire ramifications for the legality of any FDA-approved drug, such as vaccines, insulin or new Alzheimer’s drugs coming onto the market because it seeks to “turn upside down” the entire FDA approval process.
The former California attorney general acknowledged a “good chance” that the case will ultimately be decided by the Supreme Court, which last year overturned Roe v. Wade and curtailed access to abortion across the country.
“If a judge decides to substitute his preference, his personal opinion for that of scientists and medical professionals, what drug isn’t subject to some kind of legal challenge? So we have to go to court,” he said.
“What you saw by that one judge in that one court, in that one state, that’s not America,” Becerra added. “America goes by the evidence. America does what’s fair. America does what is transparent and we can show that what we do is for the right reasons.”
Sign up for our weekly newsletter to get more English-language news coverage from EL PAÍS USA Edition
Tu suscripción se está usando en otro dispositivo
¿Quieres añadir otro usuario a tu suscripción?
Si continúas leyendo en este dispositivo, no se podrá leer en el otro.
FlechaTu suscripción se está usando en otro dispositivo y solo puedes acceder a EL PAÍS desde un dispositivo a la vez.
Si quieres compartir tu cuenta, cambia tu suscripción a la modalidad Premium, así podrás añadir otro usuario. Cada uno accederá con su propia cuenta de email, lo que os permitirá personalizar vuestra experiencia en EL PAÍS.
En el caso de no saber quién está usando tu cuenta, te recomendamos cambiar tu contraseña aquí.
Si decides continuar compartiendo tu cuenta, este mensaje se mostrará en tu dispositivo y en el de la otra persona que está usando tu cuenta de forma indefinida, afectando a tu experiencia de lectura. Puedes consultar aquí los términos y condiciones de la suscripción digital.